Comparative Quantification of Plasma hnRNP B1 mRNA in Non-small Cell Lung Cancer Patients by Real-time PCR.
10.3343/kjlm.2009.29.3.249
- Author:
Jeong Man KIM
1
;
Sang Hyun HWANG
;
Eun Ju SONG
;
Sang Yull LEE
;
Yeong Dae KIM
;
Chang Hun LEE
;
Min Ki LEE
;
Chulhun L CHANG
;
Eun Yup LEE
Author Information
1. Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea.
- Publication Type:Original Article ; Comparative Study ; English Abstract
- Keywords:
Lung cancer;
hnRNP B1;
Plasma mRNA;
Cancer biomarker;
Circulating nucleic acid
- MeSH:
Adult;
Aged;
Carcinoma, Non-Small-Cell Lung/*genetics;
Female;
Heterogeneous-Nuclear Ribonucleoprotein Group A-B/*blood/genetics;
Humans;
Lung Diseases/blood/genetics;
Lung Neoplasms/*genetics;
Male;
Middle Aged;
Polymerase Chain Reaction;
RNA, Messenger/*blood/metabolism;
Tumor Markers, Biological
- From:The Korean Journal of Laboratory Medicine
2009;29(3):249-255
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Circulating cell-free nucleic acids are known to be a noninvasive diagnostic tool for cancer detection. Heterogeneous nuclear ribonucleoprotein (hnRNP) B1, a nuclear core complex, is overexpressed in early stage lung cancer. We intended to evaluate the usefulness of plasma hnRNP B1 mRNA in differentiating non-small cell lung cancer (NSCLC) from other benign lung diseases, especially pulmonary tuberculosis, which is highly prevalent in Korea and often difficult to distinguish from lung cancer. METHODS: Plasma RNA was extracted from 30 patients with NSCLC, 30 patients with benign lung diseases including pulmonary tuberculosis, and 10 healthy controls. Plasma hnRNP B1 mRNA was measured by TaqMan Gene Expression Assay (Applied Biosystems, USA), and pre-developed beta-actin (ACTB) mRNA was used for normalization. We analyzed the relative gene expression data using the delta-delta Ct method. RESULTS: Plasma hnRPN B1 mRNA was measurable in 93.3% (28/30) of NSCLC patients. Normalized 2-DeltaDeltaCt of plasma hnRPN B1 mRNA was 62.2 (95%Cl, 6.4-210.1) in NSCLC patients and 2.7 (95%Cl, 0.5-13.6) in benign lung disease patients (P<0.001, Mann-Whitney U test). CONCLUSIONS: Plasma hnRNP B1 mRNA was significantly increased in patients with lung cancer compared with that in patients with other benign lung diseases. Plasma hnRNP B1 mRNA may be useful as a potential marker for the detection of NSCLC.
